Eloralintide vs Semaglutide: Amylin Agonist vs GLP-1 Agonist (2026)

Reviewed by

Brandon Johnson — Certified Personal Trainer, Nutrition Coach & Peptide Research Consultant

Brandon Johnson is a certified personal trainer, nutrition coach, and peptide research consultant with a background in kinesiology and over 15 years of experience in fitness and wellness. He reviews all PSPeptides educational content for scientific accuracy and practical relevance.

Eloralintide vs semaglutide comes down to −20.1% at 48 weeks on eloralintide 9 mg (placebo −0.4%) against −16.9% at 68 weeks on semaglutide 2.4 mg in STEP 1 (placebo −2.4%), both on-treatment figures from two separate trials that differ in duration and size and have never been tested head-to-head. Every number below carries those conditions with it, because stripped of them the comparison misleads.

The two peptides act on different receptors. Eloralintide, Eli Lilly’s amylin receptor agonist, remains investigational, with no approval from any regulator as of October 2026, whereas semaglutide is an approved GLP-1 receptor agonist sold under the Wegovy and Ozempic brands. For laboratory work the amylin side of that contrast is supplied as a single 10 mg lyophilized eloralintide research vial, and this page treats both molecules as research materials rather than treatments.

Two Peptides, Two Pathways: The Short Version

Eloralintide vs semaglutide (October 2026)EloralintideSemaglutide
ClassOnce-weekly amylin receptor agonist, designed to preferentially activate AMY1R (Eli Lilly, LY3841136)Once-weekly GLP-1 receptor agonist
StatusInvestigational; Phase 3 ENLIGHTEN trials under way; no filing timeline disclosedApproved prescription medicine (Wegovy, Ozempic)
Trial comparedPhase 2, NCT06230523: 263 adults with obesity or overweight, no type 2 diabetes, 48 weeksSTEP 1: 1,961 adults with overweight or obesity, 68 weeks
Weight change at trial end−20.1% at 9 mg (efficacy estimand); −17.5% (treatment-regimen estimand)−16.9% at 2.4 mg weekly (trial-product estimand); −14.9% (treatment-policy estimand)
Placebo in the same trial−0.4% (efficacy estimand); −2.3% (treatment-regimen estimand)−2.4% (both estimands)
Weekly doses studied1, 3, 6 and 9 mg fixed; 6→9 mg and 3→6→9 mg escalation arms2.4 mg once weekly after escalation
TolerabilityNausea by arm 11.1–64.3% (placebo 13.5%); discontinuation for any adverse event 0–21.4% (placebo 7.7%)Nausea 44.1% (placebo 17.4%); discontinuation for adverse events 7.0% (placebo 3.1%)
Combination precedentWith tirzepatide (EloraTZP Phase 2b, type 2 diabetes)With cagrilintide (CagriSema, REDEFINE 1)
Studied with each otherNo human trial has combined eloralintide with semaglutideNo human trial has combined semaglutide with eloralintide
Available at PSPeptides as10 mg lyophilized vialLyophilized research vial

Sources: Lilly, “What to know about eloralintide” (updated September 2026); Lilly press release, Nov 6, 2025; Billings et al., The Lancet 2025; Wilding et al., N Engl J Med 2021; Garvey et al., N Engl J Med 2025; Lilly press release, Sept 30, 2026. Cross-trial values are indicative only.

Three conditions sit under every row. STEP 1 ran 68 weeks in 1,961 people; the eloralintide Phase 2 trial ran 48 weeks in 263, with arms of 24 to 54. Both trials report two estimands, so the comparison pairs like with like: on treatment, −20.1% against −16.9%; counting everyone randomised, −17.5% against −14.9%. And the placebo responses (−2.4% against −0.4% on treatment) are not alike. An eloralintide vs semaglutide table is therefore a listing of two experiments, not a ranking.

Eloralintide vs semaglutide comparison: amylin receptor agonist against GLP-1 receptor agonist trial data

Amylin Receptor Agonist Against GLP-1 Receptor Agonist

Lilly’s own description of eloralintide is a molecule “designed to preferentially activate the amylin 1 receptor (AMY1R)”, one that in its trials “was self-injected once weekly” (Lilly, What to know about eloralintide). It engages amylin signalling, a pathway associated with satiety, whereas semaglutide engages the GLP-1 receptor, one of the incretin receptors, so the two are not interchangeable in the way two GLP-1 agonists might be.

That is the practical point of any eloralintide vs semaglutide study: one probes amylin receptor biology and the other GLP-1 receptor biology, and the published data on each were generated without reference to the other. Our eloralintide research guide gives the receptor-level detail and its selectivity caveats, and the sections below keep the two datasets separate for the same reason.

Eloralintide vs Semaglutide: 48 Weeks Against 68 Weeks

The eloralintide figure comes from NCT06230523, a 48-week, placebo-controlled Phase 2 trial in 263 adults with obesity or overweight and no type 2 diabetes, in which fixed 9 mg weekly produced −20.1% against −0.4% for placebo on the efficacy estimand (Lilly press release, Nov 6, 2025). The treatment-regimen estimand, which includes participants who discontinued, gave −17.5% against −2.3% (Billings et al., The Lancet 2025).

The semaglutide figure comes from STEP 1, in which 1,961 adults with overweight or obesity and without type 2 diabetes received semaglutide 2.4 mg once weekly or placebo for 68 weeks: −14.9% against −2.4% on the treatment-policy estimand, which counts everyone randomised, and −16.9% against −2.4% on the trial-product estimand, which measures participants while on treatment (Wilding et al., N Engl J Med 2021). Both trials excluded type 2 diabetes, which makes this one of the cleaner cross-trial pairings, though the eloralintide vs semaglutide numbers should still be read side by side rather than subtracted.

TrialWeekly armDurationPopulationWeight changePlaceboAnalysis
Eloralintide Phase 21 mg48 weeks263 adults, no type 2 diabetes−9.5%−0.4%Efficacy estimand
Eloralintide Phase 23 mg48 weeks263 adults, no type 2 diabetes−12.4%−0.4%Efficacy estimand
Eloralintide Phase 26 mg48 weeks263 adults, no type 2 diabetes−17.6%−0.4%Efficacy estimand
Eloralintide Phase 29 mg48 weeks263 adults, no type 2 diabetes−20.1%−0.4%Efficacy estimand
Eloralintide Phase 26→9 mg48 weeks263 adults, no type 2 diabetes−19.9%−0.4%Efficacy estimand
Eloralintide Phase 23→6→9 mg48 weeks263 adults, no type 2 diabetes−16.4%−0.4%Efficacy estimand
Eloralintide Phase 29 mg48 weeks263 adults, no type 2 diabetes−17.5%−2.3%Treatment-regimen estimand
Semaglutide STEP 12.4 mg68 weeks1,961 adults, no type 2 diabetes−16.9%−2.4%Trial-product estimand (on treatment)
Semaglutide STEP 12.4 mg68 weeks1,961 adults, no type 2 diabetes−14.9%−2.4%Treatment-policy estimand

Sources: Lilly press release, Nov 6, 2025 and Billings et al., The Lancet 2025 (eloralintide); Wilding et al., N Engl J Med 2021 (semaglutide). Separate trials of different length, size and analysis; indicative only, not head-to-head.

Matched by estimand, the eloralintide vs semaglutide gap at the top dose is about three percentage points either way (−20.1% against −16.9% on treatment, −17.5% against −14.9% counting everyone randomised), and the 1 mg and 3 mg eloralintide arms (−9.5% and −12.4%) sit below semaglutide 2.4 mg. But the eloralintide trial stopped 20 weeks earlier, its arms were a fraction of STEP 1’s size and its placebo group barely moved, so the defensible statement is that both agents produced large, placebo-separated weight loss in their own trials.

Eloralintide 48-week Phase 2 weight change by arm beside semaglutide STEP 1 68-week result with placebo values

Tolerability: What Each Trial Actually Reported

The two trials reported tolerability at different levels of detail, so the eloralintide vs semaglutide safety picture sets a single semaglutide dose against six eloralintide arms. The Lancet paper itemises nausea for every eloralintide arm along with discontinuation for any adverse event; STEP 1 reports nausea, discontinuation for adverse events, discontinuation for gastrointestinal events and serious adverse events for its single 2.4 mg arm.

MeasureEloralintide Phase 2 (48 weeks)Semaglutide STEP 1 (68 weeks)
Nausea, placebo arm13.5%17.4%
Nausea, 1 mg and 3 mg11.1% and 13.0%—
Nausea, fixed 6 mg64.3%—
Nausea, fixed 9 mg33.3%—
Nausea, 6→9 mg54.2%—
Nausea, 3→6→9 mg25.0%—
Nausea, all active arms pooled32.7%44.1% (single 2.4 mg arm)
Discontinuation for any adverse eventPooled 10.1% vs placebo 7.7%; by arm 0% (3 mg) to 21.4% (6 mg)7.0% vs 3.1% placebo
Discontinuation for gastrointestinal eventsNot reported separately4.5% vs 0.8% placebo
Serious adverse events5.3% pooled vs 5.8% placebo; no deaths9.8% vs 6.4% placebo

Sources: Billings et al., The Lancet 2025 (safety population N=260; with 24 to 54 people per arm, the percentages carry wide uncertainty); Wilding et al., N Engl J Med 2021. The measures differ between trials and are not interchangeable.

Within the eloralintide data the pattern follows dose and speed. At 1 and 3 mg, nausea (11.1% and 13.0%) sat at or below the placebo rate of 13.5%; fixed 6 mg produced the highest rate, 64.3%; fixed 9 mg produced 33.3%; and the slowest escalation, 3→6→9 mg, produced 25.0%. The eloralintide side-effects review adds the vomiting, constipation and fatigue rows for each arm.

Set like against like, discontinuation for any adverse event was 7.0% on semaglutide against 3.1% on placebo over 68 weeks, and 10.1% pooled on eloralintide against 7.7% over 48 weeks; nausea was 44.1% against 17.4% for semaglutide and 32.7% pooled against 13.5% for eloralintide. Different durations and dose sets mean neither row ranks the molecules, but eloralintide’s record is the one with arm-by-arm detail, and its slow 3→6→9 mg arm held nausea to 25.0%.

Weekly Dosing: 1 to 9 mg Against 2.4 mg

Both peptides are given by once-weekly subcutaneous injection, but the milligram ranges say nothing about relative potency because they act on different receptors. Eloralintide’s Phase 2 doses were 1, 3, 6 and 9 mg weekly; its 6→9 mg arm switched dose at week 20, and its 3→6→9 mg arm switched at weeks 4 and 8 before staying on 9 mg through week 48 (Billings et al. 2025).

Semaglutide in STEP 1 was given at 2.4 mg once weekly after escalation, the maintenance dose behind both the −16.9% and −14.9% figures; our semaglutide dosage and reconstitution guide handles the practical side of that vial. On the eloralintide side, adding 1.0 mL of bacteriostatic water to the 10 mg vial yields 10 mg/mL, which makes 3, 6 and 9 mg equal to 30, 60 and 90 units on a U-100 syringe, as worked through in the eloralintide dosage guide.

An eloralintide vs semaglutide dosing table is therefore two unrelated scales placed next to each other. The trial-relevant lesson from eloralintide is that the route to 9 mg mattered as much as the dose, since fixed 9 mg, 6→9 mg and 3→6→9 mg produced −20.1%, −19.9% and −16.4% with nausea of 33.3%, 54.2% and 25.0% respectively.

Why Amylin and GLP-1 Get Combined: CagriSema and EloraTZP

The clearest sign that the two pathways are complementary rather than competing is that both companies have paired an amylin analogue with an incretin. In REDEFINE 1, cagrilintide 2.4 mg plus semaglutide 2.4 mg weekly, the combination known as CagriSema, produced −20.4% against −3.0% for placebo over 68 weeks in 3,417 adults without type 2 diabetes, with gastrointestinal adverse events in 80% versus 40% (Garvey et al., N Engl J Med 2025).

Lilly’s pairing puts eloralintide with tirzepatide. In the 48-week EloraTZP Phase 2b trial of 367 adults with obesity or overweight and type 2 diabetes, eloralintide 9 mg plus tirzepatide 15 mg produced −23.3% where tirzepatide 15 mg alone produced −14.8% and placebo −3.0% (Lilly press release, Sept 30, 2026). Because that population had diabetes, its figures are not comparable with REDEFINE 1 or with the eloralintide Phase 2 trial.

What does not exist is any human study of eloralintide with semaglutide itself: as of October 2026 no trial has combined eloralintide with semaglutide, retatrutide or cagrilintide, and tirzepatide is the only partner in the published record (the triple agonist is covered separately in our eloralintide vs retatrutide comparison). An eloralintide vs semaglutide pairing therefore has no clinical template for dose ratio, sequencing or tolerability, and the closest documented precedents are CagriSema, reviewed in our CagriSema vs semaglutide comparison, and EloraTZP.

Amylin plus incretin combinations: CagriSema REDEFINE 1 and EloraTZP Phase 2b results beside eloralintide and semaglutide monotherapy

Approval Status: Marketed Medicine Against Phase 3 Candidate

On status the eloralintide vs semaglutide contrast is total. Semaglutide is an approved prescription medicine marketed as Wegovy and Ozempic. Eloralintide is investigational: Lilly’s page, updated September 2026, says “Lilly is currently investigating eloralintide in Phase 3 trials,” its forward-looking statement gives “no assurance” of approval, and the company has published neither the Phase 3 doses nor any readout or filing dates.

The earliest estimated completion in the ENLIGHTEN Phase 3 program belongs to ENLIGHTEN-2 (NCT07282600), a placebo-controlled trial of about 1,035 participants with type 2 diabetes that began December 15, 2025 and is expected to complete in February 2028. The remaining trials run later, and the eloralintide research guide lists every registry date alongside Lilly’s statements.

Which Peptide for Which Research Question

Research questionBetter-documented candidateReason
Amylin receptor biologyEloralintideAMY1R-preferential design; placebo-controlled monotherapy data at four fixed doses over 48 weeks
GLP-1 receptor pharmacologySemaglutideGLP-1 receptor agonist with 68-week placebo-controlled data at 2.4 mg
Largest weight change in its own trialEloralintide, indicatively−20.1% at 48 weeks (placebo −0.4%) against −16.9% at 68 weeks (placebo −2.4%), both on treatment; different trials
Longest follow-upSemaglutide68 weeks against 48
Largest trial populationSemaglutide1,961 participants against 263
Arm-by-arm nausea dataEloralintideNausea reported for all seven Phase 2 arms
Approved reference compoundSemaglutideMarketed medicine; eloralintide is investigational
Amylin-plus-incretin templateNeither with the otherCagriSema (cagrilintide + semaglutide) and EloraTZP (eloralintide + tirzepatide) are the published precedents
Pairing eloralintide with semaglutideNo templateNo human trial has combined them

A planning aid for laboratory work, built only from the references below; it is not treatment guidance.

A laboratory working on amylin receptor biology has no eloralintide vs semaglutide decision to make, and the reverse holds for GLP-1 work. If the question is which record runs longer and wider, STEP 1’s 68 weeks in 1,961 people outweighs 48 weeks in 263; if it is arm-by-arm tolerability, the Lancet paper wins. Our semaglutide vs retatrutide vs tirzepatide comparison places semaglutide among the incretin agonists, and the weight-loss peptide overview surveys the wider field.

Eloralintide 10 mg and semaglutide lyophilized research vials with certificates of analysis and bacteriostatic water

Research Vials for Both Sides of the Comparison

PSPeptides stocks eloralintide as a 10 mg lyophilized research vial synthesized in a cGMP-compliant facility in Temecula, California, and each lot is screened by independent accredited laboratories: purity by HPLC at a 99%+ minimum, identity by mass spectrometry, plus endotoxin, sterility, heavy-metal and fentanyl testing, as set out on the certifications page. A semaglutide research vial is stocked for the GLP-1 side of the comparison.

The same order can carry bacteriostatic water and U-100 insulin syringes, and the free peptide calculator turns any trial dose into syringe units at whatever concentration is chosen. Orders placed before 2 PM EST ship the same day with free US shipping, payment can be made by card, Afterpay or Klarna, and the product page carries current pricing and each lot’s certificate of analysis.

Buy eloralintide 10 mg · Buy semaglutide

Eloralintide and Semaglutide: Frequently Asked Questions

Did eloralintide produce more weight loss than semaglutide in trials?

In its own 48-week Phase 2 trial, eloralintide 9 mg produced −20.1% against −0.4% for placebo on the efficacy estimand in adults without type 2 diabetes, while semaglutide 2.4 mg produced −16.9% against −2.4% over 68 weeks in STEP 1 on the comparable trial-product estimand. The trials differ in duration, size and placebo response, so the eloralintide vs semaglutide difference is indicative, not a head-to-head result.

Has eloralintide been studied together with semaglutide?

No. As of October 2026 no human trial has combined eloralintide with semaglutide, retatrutide or cagrilintide; the only eloralintide combination tested is with tirzepatide, in the EloraTZP Phase 2b trial. The nearest precedent for an amylin analogue alongside semaglutide is CagriSema, which uses cagrilintide.

Is eloralintide a GLP-1 agonist like semaglutide?

No. Eloralintide is an amylin receptor agonist that Lilly designed to preferentially activate the amylin 1 receptor, whereas semaglutide is a GLP-1 receptor agonist. The two act on different receptor systems, which is why the industry has paired amylin analogues with incretin agonists rather than substituting one for the other.

What weekly doses were used for eloralintide and semaglutide?

Eloralintide was studied at 1, 3, 6 and 9 mg once weekly in Phase 2, including a 6→9 mg arm and a 3→6→9 mg arm. Semaglutide in STEP 1 was given at 2.4 mg once weekly after escalation; the milligram figures are not comparable across two different receptor classes.

References

  1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2032183
  2. Eli Lilly press release, Nov 6, 2025 — “Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight.” https://investor.lilly.com/node/53246
  3. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631–2643. https://doi.org/10.1016/S0140-6736(25)02155-5
  4. Eli Lilly, “What to know about eloralintide” (last updated September 2026). https://www.lilly.com/news/stories/what-to-know-about-eloralintide
  5. Garvey WT, et al. REDEFINE 1. N Engl J Med 2025. https://doi.org/10.1056/NEJMoa2502081
  6. Eli Lilly press release, Sept 30, 2026 — “Lilly’s EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction…” https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide
  7. ClinicalTrials.gov — ENLIGHTEN-2 (NCT07282600). https://clinicaltrials.gov/study/NCT07282600. Accessed October 19, 2026.

All PSPeptides products are sold exclusively for research and laboratory use.